The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: A reactive metabolite in felbamate bioactivation

被引:26
作者
Dieckhaus, CM
Santos, WL
Sofia, RD
Macdonald, TL
机构
[1] Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA
[2] Wallace Labs, Res & Dev, Cranbury, NJ 08512 USA
关键词
D O I
10.1021/tx000139n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
4-Hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one has been proposed to be a reactive metabolite of the anti-epileptic drug felbamate [Thompson et al. (1996) Chem. Res. Toxicol. 9, 1225-1229]. 4-Hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one exists in equilibrium with 3-oxo-2-phenylpropyl aminooate, which is known to eliminate to generate 2-phenylpropenal. Thus, this species is postulated to be a latent form of the ultimate reactive metabolite, 2-phenylpropenal. The chemistry of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one is proposed to parallel that of 4-hydroxycyclophosphamide, the bioactivated form of cyclophosphamide that undergoes ring-opening to aldophosphamide and subsequent elimination to afford 2-propenal (acrolein). The work presented here reports the chemical synthesis of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one and demonstrates that under buffered conditions it exists in equilibrium with 3-oxo-2-phenylpropyl aminooate. The rate-limiting step in the decomposition of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one is the irreversible fl-elimination from 3-oxo-2-phenylpropyl aminooate to 2-phenylpropenal. We have found the half-life of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one to be 4.6 +/- 0.4 h under in vitro conditions that mimic the physiological setting. As a consequence of the relatively long half-life of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one, we have sought evidence for the significance of this pathway in experimental and clinical conditions. We report here the observation of this metabolite in the urine of rats being treated with 3-hydroxy-2-phenylpropyl aminooate, the esterase-mediated metabolite of felbamate, and in the urine of patients undergoing felbamate therapy. In addition, we have shown that 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one is toxic to cultured cells in a time-dependent manner, most likely as a result of its decomposition to 2-phenylpropenal. Taken together, the data support the hypothesis that 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one represents a "time-release" form of 2-phenylpropenal capable of traveling to distal sites from its locus of bioactivation and thereby mediates felbamate associated toxicities.
引用
收藏
页码:958 / 964
页数:7
相关论文
共 19 条
  • [11] Felbamate-associated fatal acute hepatic necrosis
    ONeil, MG
    Perdun, CS
    Wilson, MB
    McGown, ST
    Patel, S
    [J]. NEUROLOGY, 1996, 46 (05) : 1457 - 1459
  • [12] APLASTIC-ANEMIA IN A PATIENT RECEIVING FELBAMATE FOR COMPLEX PARTIAL SEIZURES
    PENNELL, PB
    OGAILY, MS
    MACDONALD, RL
    [J]. NEUROLOGY, 1995, 45 (03) : 456 - 460
  • [13] PETERS T, 1996, ALL ABOUT ALBUMIN
  • [14] SAYER JM, 1973, J AM CHEM SOC, V95, P4278
  • [15] METABOLISM OF OXAZAPHOSPHORINES
    SLADEK, NE
    [J]. PHARMACOLOGY & THERAPEUTICS, 1988, 37 (03) : 301 - 355
  • [16] Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids
    Thompson, CD
    Barthen, MT
    Hopper, DW
    Miller, TA
    Quigg, M
    Hudspeth, C
    Montouris, G
    Marsh, L
    Perhach, JL
    Sofia, RD
    Macdonald, TL
    [J]. EPILEPSIA, 1999, 40 (06) : 769 - 776
  • [17] Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration
    Thompson, CD
    Gulden, PH
    Macdonald, TL
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1997, 10 (04) : 457 - 462
  • [18] Thompson CD, 2000, DRUG METAB DISPOS, V28, P434
  • [19] Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate
    Thompson, CD
    Kinter, MT
    Macdonald, TL
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (08) : 1225 - 1229